an approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, late...st update: 21 January 2022
Available in English, French, Spanish
more
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama...nid in young children with multidrug- and rifampicin-resistant TB and decentralized and family-centred, integrated models of care for TB case detection and prevention in children and adolescents.
more
The practical guidance in the operational handbook aims to inform the development or revision of national policies and related implementation guidance on the management of TB in children and adolescents under programmatic circumstances and at different levels of the ...ht medbox">health system. The operational handbook can also help countries adequately plan for the uptake of interventions to better address the specific needs of children and adolescents with or at risk of TB. It can contribute to national efforts to build capacity among national and subnational programme managers and among health workers at all levels of the health care system.
more
In 2018, the WHO European Healthy Cities Network adopted the political vision of the Network until 2030 that is fully aligned with the United Nations 2030 Agenda for Sustainable Development: the Copenhagen Consensus of Mayors: Healthier and Happier ...Cities for All. The vision is built around six themes. This compendium comprises tools, resources and networks that are related to one of the themes - place - from across the WHO European Healthy Cities Network and wider from 2010 to 2020. It is part of the support package for implementation of the place theme in Phase VII (2019–2024) of the WHO European Healthy Cities Network.
more
This guideline aims to improve the quality of essential, routine postnatal care for women and newborns with the ultimate goal of improving maternal and newborn health and well-being. It recognizes a “positive postnatal experience” as a significa...nt end point for all women giving birth and their newborns, laying the platform for improved short- and long-term health and well-being. A positive postnatal experience is defined as one in which women, newborns, partners, parents, caregivers and families receive information, reassurance and support in a consistent manner from motivated health workers; where a resourced and flexible health system recognizes the needs of women and babies, and respects their cultural context.
This is a consolidated guideline of new and existing recommendations on routine postnatal care for women and newborns receiving facility- or community-based postnatal care in any resource setting.
more
WHO has developed standardized health kits of medicines and medical supplies to meet different health needs in humanitarian emergencies and disaste...rs.
These kits are developed to provide reliable and affordable medicines and supplies quickly to those in need. The kits are used by United Nations agencies, nongovernmental organizations and national governments.
Based primarily on WHO’s Essential Medicines list and guidelines on treatment of specific medical conditions, the contents of the kits are frequently reviewed and updated to adapt to changing needs based on experience in emergency situations.
A certain number of kits are prepositioned in strategic locations to be mobilized quickly in times of need. Long term agreements with suppliers are also in place to ensure rapid shipment wherever needed.
more
Member States have requested WHO policy guidance on how to facilitate the implementation of national AMS activities in an integrated and programmatic approach. This policy guidance responds to that demand from Member States and is anchored in public... health guiding principles in the human health sector. It provides evidence-based and pragmatic recommendations to drive comprehensive and integrated AMS activities under the purview of a central national coordination unit, National AMR steering or coordinating committees or other equivalent national authorities.
Please note that this course is part of a training package, so please register for the complementary course Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit so that you can complete your learning journey.
more
In 2009, WHO’s Second International Conference on Buruli Ulcer Control and Research resolved to strengthen the capacity of national laboratories to confirm cases of the disease, but advised that “efforts are still needed to develop simple diagno...stic tools usable in the field as well as disability prevention methods”.
In 2013, WHO and the Foundation for Innovative New Diagnostics convened a meeting of Buruli ulcer experts in Geneva, Switzerland (9) at which two priority unmet needs in diagnosis were identified:
a diagnostic test for early detection of Buruli ulcer in symptomatic patients with sufficient positive predictive value to put patients on appropriate treatment; and
a screening test at the primary health care or community level for symptomatic patients with ulcer
more
Acupuncture has been practised for more than 2500 years in the Western Pacific Region and has become a global therapeutic method in recent decades. However, it was reportedthat acupuncturists differed by up to 25% in the acupuncture points they used, raising doubts and uncertainty regarding the effi...cacy and safety of acupuncture treatment, as well as causing difficulties in the fields of acupuncture research and education.
more
Interactive platform visualizing mortality data. The WHO Mortality Database is a compilation of mortality data by country and area, year, sex, age and cause of death, as transmitted annually by national authorities from their civil registration and ...vital statistics system. It comprises data since 1950 to date.
more
What are the symptoms of monkeypox? Who is at risk and how can we protect ourselves? Why is WHO concerned about it? WHO’s Dr Rosamund Lewis expla...ins in Science in 5.
more
Which communities are most at risk of Monkeypox in the current outbreak and why? WHO’s Andy Seale explains how we can support the communities at risk in Science in 5.
WHO’s Dr Philippa Easterbrook gives a situation update on the recent hepatitis outbreak affecting children including possible causes and steps parents, caregivers and countries should take.
mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to us about mRNA technologies. What is the future?
The WHO BioHub Biosafety & Biosecurity: criteria and operational modalities sets out the requirements to which laboratories wishing to receive biological materials as part of this international exchange system should abide, to ensure safe and secure... operations. These provisions are in accordance with the recommendations of the WHO Laboratory Biosafety Manual 4th edition (LBM4), adopting an evidence- and risk-based approach to enable scalable and adaptable biosafety provisions and actions, proportionate to the assessed risk
more
In 2013, WHO and the Foundation for Innovative New Diagnostics convened a meeting of Buruli ulcer experts in Geneva, Switzerland (9) at which two priority unmet needs in diagnosis were identified:
a diagnostic test for early detection of Buruli ulc...er in symptomatic patients with sufficient positive predictive value to put patients on appropriate treatment; and
a screening test at the primary health care or community level for symptomatic patients with ulcer
In March 2018, they convened a global meeting with the aim of establishing an action plan to develop new diagnostic solutions for Buruli ulcer and to create a framework of collaboration to address unmet needs in diagnostics for the disease. The participants agreed to develop a target product profile (TPP) to address the need for a rapid diagnostic test for use at the primary health-care level.
more
The guidance notes describe key actions that policy-makers at national and subnational levels can take in relation to: diagnostic testing for COVID-19, clinical management of COVID-19, meeting targets for vaccination against COVID-19, maintaining infection control measures for COVID-19 in ...s="attribute-to-highlight medbox">health-care settings, building confidence through risk communication and community involvement, and ensuring that all health-care workers are aware of the risks of COVID-19.
This guidance note focuses on the following areas: COVID-19 diagnostic testing, clinical management of COVID-19, achieving COVID-19 vaccination targets, maintaining COVID-19 infection control measures in health-care settings, building confidence through risk communication and community engagement, and managing COVID-19 infodemia. This guidance note focuses on risk communication and community engagement in the context of COVID-19.
more